Sign In
Buy NAVB
$0.0001
+0 (+0%)
At Close: Dec 30, 2025
Navidea Biopharmaceuticals' (NAVB) Interim CEO Jed Latkin on Q2 2018 Results - Earnings Call Transcript
12:00am, Thursday, 16'th Aug 2018Navidea Biopharmaceuticals Receives Listing Noncompliance Notice from NYSE
12:00am, Wednesday, 15'th Aug 2018Navidea Biopharmaceutical Q2 EPS $(0.02), Same YoY, Sales $542.127M Up From $611.599K YoY
12:00am, Wednesday, 08'th Aug 2018Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q1 2018 Results - Earnings Call Transcript
12:00am, Wednesday, 09'th May 2018Navidea Biopharmaceutical Q1 EPS $(0.04), Made $276.445K Sales
12:00am, Tuesday, 08'th May 2018Navidea Biopharma Reports Deal To Sublicense NAV4694 Global Development Rights
12:00am, Monday, 16'th Apr 2018Navidea Biopharmaceuticals Reports Q4 EPS $(0.03) vs $(0.02) In Prior Year Period, Sales $395K vs $1.03M In Prior Year Period
12:00am, Thursday, 08'th Mar 2018Navidea Biopharm (NAVB) Presents At 10th Annual Biotech Showcase 2018 - Slideshow
12:00am, Tuesday, 09'th Jan 2018Cardinal Health: A Dividend Aristocrat The Risk Is Already Priced In-Part 2 Of 7
09:43pm, Wednesday, 22'nd Nov 2017
Cardinal Health Inc. (CAH) is a Dividend Aristocrat that has increased its dividend for 32 consecutive years and is currently yielding 3.3%.
